Volume : IX, Issue : I, January - 2019

Current status of sodium glucose co-transporter 2 inhibitors in management of diabetes type 2.

Jarnail Singh

Abstract :

Diabetes is common worldwide, affecting millions of people, with significant systemic complications. Many pharmacological approaches are available to treat it, including insulin and antihyperglycemic agents. Sodium glucose co–transporter 2 inhibitors are a novel approach in the management of type 2 diabetes, and such agents have been approved by for clinical use since 2013. But SGLT 2 inhibitors use is associated with serious and significant adverse drug reactions. The US FDA warnings have been recommended on labels of canagliflozin and dapagliflozin. Long term clinical studies have been conducted to evaluate the safety and efficacy of SGLT 2 inhibitors. Purpose of this review is to elaborate usefulness of SGLT 2 inhibitors in management of type 2 diabetes mellitus with a focus on safety in different populations affected by the disease.

Keywords :

Article: Download PDF   DOI : 10.36106/ijar  

Cite This Article:

CURRENT STATUS OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN MANAGEMENT OF DIABETES TYPE 2., Jarnail Singh INDIAN JOURNAL OF APPLIED RESEARCH : Volume-9 | Issue-1 | January-2019

Number of Downloads : 295

References :